Impel NeuroPharma Inc.

IMPL 4 | $0.2411 -77.19% 860K

(0.0% 1d) (0.0% 1m) (-77.2% 1y) (0.0% 2d) (10.1% 3d) (0.0% 7d) (-28.63% volume)
Earnings Calendar: 2024-03-22
Market Cap: $ 5,762,297
https://impelnp.com
Sec Filling | Patents | n/a employees

(US) Impel NeuroPharma, Inc. is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initial focus on diseases of the CNS. The Company’s strategy is to rapidly advance its product candidate pipeline that pairs its proprietary Precision Olfactory Delivery (POD®) system with well-established therapeutics, including TRUDHESA™ for the acute treatment of migraine, INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease.

parkinson treatment

add to watch list Paper trade email alert is off

Acurx Pharmaceuticals LLC

ACXP | $2.02 -5.16% -5.45% 94K

Professional, Scientific, and T...

(0.0% 1d) (-2.4% 1m) (-33.4% 1y) (-5.6% 2d) (-5.6% 3d) (22.9% 7d) (-34.38% volume)
Earnings Calendar: 2024-03-18
Market Cap: $ 31,829,346
https://www.acurxpharma.com
Sec Filling | Patents | 3 employees

Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections. The Company's approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme and its R&D pipeline includes early stage antibiotic candidates that target other Gram-positive bacteria, including Methicillin-Resistant Staphylococcus aureus (MRSA), Vancomycin-Resistant Enterococcus (VRE) and Penicillin-Resistant Streptococcus pneumoniae (PRSP).

injection

add to watch list Paper trade email alert is off

Alzamend Neuro Inc

ALZN | $0.6894 -0.23% -0.23% 28K

Professional, Scientific, and T...

(0.0% 1d) (-35.2% 1m) (13.3% 1y) (-1.4% 2d) (-1.4% 3d) (-8.2% 7d) (3.58% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 4,734,004
https://alzamend.com/
Sec Filling | Patents | 3 employees

(United States) Alzamend Neuro is a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer’s disease. With its product candidates, the company aims to bring treatments or cures to market at a reasonable cost as quickly as possible. Its current pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s. Both of its product candidates are licensed from the University of South Florida Research Foundation, Inc. pursuant to royalty-bearing exclusive worldwide licenses.

treatment msa vaccine t-cell lithium alzheimer neurodegenerative alzheimer’s

add to watch list Paper trade email alert is off

Doximity Inc - Class A

DOCS | News | $24.63 -0.77% -0.12% 1.7M

Professional, Scientific, and T...

(0.0% 1d) (-12.1% 1m) (-32.4% 1y) (-1.6% 2d) (-1.6% 3d) (-3.1% 7d) (Infinity% volume)
Earnings Calendar:
Market Cap: $ 3,008,839,371
https://www.doximity.com
Sec Filling | Patents | 2021 employees

Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members include over 80% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and conduct virtual patient visits. Doximity's mission is to help doctors be more productive so they can provide better health care for their patients.

urea

add to watch list Paper trade email alert is off

E-Home Household Service Holdings Ltd

EJH | $3.135 5.2% 4.94% 1.8M

Professional, Scientific, and T...

(0.0% 1d) (158.7% 1m) (631.3% 1y) (0.0% 2d) (0.0% 3d) (1.0% 7d) (-4.67% volume)
Earnings Calendar:
Market Cap: $ 430,015,513

Sec Filling | Patents | n/a employees

add to watch list Paper trade email alert is off

Finch Therapeutics Group Inc

FNCH | $2.205 -6.57% -7.03% 30K

Professional, Scientific, and T...

(0.0% 1d) (-14.2% 1m) (-84.3% 1y) (0.0% 2d) (-11.1% 3d) (-0.2% 7d) (-76.8% volume)
Earnings Calendar: 2023-03-30
Market Cap: $ 3,540,707
https://finchtherapeutics.com
Sec Filling | Patents | n/a employees

Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch’s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection (CDI), and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first of two pivotal trials to support the development of CP101 for the prevention of recurrent CDI. Finch plans to initiate a Phase 3 trial, referred to as PRISM4, as its second pivotal trial of CP101 for recurrent CDI. Finch is also developing CP101 for the treatment of chronic hepatitis B virus, and FIN-211 for the treatment of the gastrointestinal and behavioral symptoms of autism spectrum disorder. In partnership with Takeda, Finch is advancing FIN-524 and FIN-525 for the treatment of ulcerative colitis and Crohn’s disease, respectively.

hepatitis gastrointestinal treatment injection

add to watch list Paper trade email alert is off

Singular Genomics Systems Inc

OMIC | $0.3925 0.93% 0.92% 120K

Professional, Scientific, and T...

(0.0% 1d) (-18.8% 1m) (-61.9% 1y) (0.0% 2d) (0.0% 3d) (6.1% 7d) (-53.63% volume)
Earnings Calendar: 2024-03-18
Market Cap: $ 29,016,959
https://singulargenomics.com
Sec Filling | Patents | 138 employees

Singular Genomics is a life science technology company that is leveraging novel, next generation sequencing (NGS) and multiomics technologies to build products that empower researchers and clinicians. The Singular Sequencing Engine is the foundational platform technology that forms the basis of Singular Genomics’ products in development and Singular Genomics’ core product tenets: accuracy, speed, flexibility and scale. Singular Genomics’ first integrated solution is targeted at the NGS market and comprises an instrument and an associated menu of consumable kits, which Singular Genomics refers to collectively as the G4 Integrated Solution. A second integrated solution in development comprises an instrument and an associated menu of consumable kits, which Singular Genomics refers to collectively as the PX Integrated Solution. The PX Integrated Solution combines single cell analysis, spatial analysis, genomics and proteomics in one integrated instrument providing a versatile multiomics solution.

t-cell

add to watch list Paper trade email alert is off

Quantum-Si Incorporated - Class A

QSI | $1.57 3.97% 3.82% 730K

Professional, Scientific, and T...

(0.0% 1d) (-17.4% 1m) (-1.9% 1y) (3.3% 2d) (2.6% 3d) (-5.4% 7d) (Infinity% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 191,276,895
https://quantum-si.com
Sec Filling | Patents | 115 employees

Quantum-Si Incorporated develops protein sequencing platform. The Company offers semiconductor chip designed to enable single-molecule next-generation protein sequencing and genomics, and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing.

drug discovery diagnostics semiconductor chip

add to watch list Paper trade email alert is off

Beauty Health Company (The) - Class A

SKIN | $3.25 -5.25% -5.54% 1.2M

Professional, Scientific, and T...

(0.0% 1d) (-26.5% 1m) (-74.8% 1y) (0.0% 2d) (-1.2% 3d) (-8.1% 7d) (110.46% volume)
Earnings Calendar: 2024-03-12
Market Cap: $ 401,242,800
https://www.beautyhealth.com/
Sec Filling | Patents | n/a employees

BeautyHealth is a category-creating beauty health company focused on bringing innovative products to market. Its flagship brand, HydraFacial, is a non-invasive and approachable beauty health platform and ecosystem with a powerful community of estheticians, consumers and partners, bridging medical and consumer retail to democratize and personalize skin care solutions for the masses. Leading the charge in beauty health as a category-creator, HydraFacial uses a unique delivery system to cleanse, extract, and hydrate with their patented hydradermabrasion technology and super serums that are made with nourishing ingredients, providing an immediate outcome and creating an instantly gratifying glow in just three steps and 30 minutes. HydraFacial® and Perk™ products are available in over 87 countries with over 16,000 delivery systems globally and millions of treatments performed each year.

brands msa skin treatment 3d

add to watch list Paper trade email alert is off